Hypochondroplasia
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (7)
Total enrollment: 608 patients across 7 trials
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
An Interventional Study of Infigratinib in Children With Hypochondroplasia
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
Prospective Clinical Assessment Study in Children With Hypochondroplasia
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.